A strategy that assigned dose intensification to patients with hidradenitis suppurativa (HS) and an end-of-dose effect and long-term antibiotics to those without was associated with improvement in partial responders to biologics. "These findings support a personalized approach to biologic optimization…
A history of accomplishments rooted in science Genmab Hosts Plenary and Life Science Fair on AI’s Role in the Future of Healthcare and Labs COPENHAGEN, Denmark; October 28, 2026 The safety profile of petosemtamab when administered in combination with pembrolizumab was generally…
Neil Stone, Honorary Associate Professor at University College London, shared on X: “A real cancer breakthrough this week: petosemtamab plus pembrolizumab halved the risk of death in a phase 3 head and neck cancer trial. No ivermectin in sight.” The trial met…
— Phase II LOTUS data suggest IL-1 beta inhibition could become an important new approach Phase II findings presented at the European Academy of Dermatology and Venereology meeting in Vienna showed promising early efficacy with abdakibart, an investigational interleukin (IL)-1 beta…
Alexa Kimball, MD, MPH, reviews tulisokibart safety in hidradenitis suppurativa, its potential in patients with IBD, and what phase 3 trials must answer. Safety data from the phase 2b MK-7240-012 trial (NCT06956235) of tulisokibart in moderate to severe hidradenitis suppurativa (HS) showed adverse…
Gut-derived metabolites have been linked to greater disease severity in multiple sclerosis. Learn how metabolomic profiles could guide biomarker research. This site is intended for healthcare professionals Metabolomic Profiles in Multiple Sclerosis Linked to Disease Severity - This cross-sectional study analysed…
Interested in Annexon, Inc.? Here are five stocks we like better. Annexon expects a key Phase III readout in Q4 2026 for vonaprument in geographic atrophy. ARCHER II enrolled 659 patients and uses confirmed loss of 15 vision-chart letters at month 15 as its primary…
Nathan explains why a TETON-2 post hoc analysis of recurrent events, 126 vs 161 with placebo, supports continuing inhaled treprostinil after progression. A post hoc analysis of the phase 3 TETON-2 trial presented at the CHEST 2026 Annual Meeting in Phoenix supports continuing inhaled…
Medha Baranwal holds a Bachelor’s degree in Biomedical Sciences from the University of Delhi and a Master’s degree in Biotechnology from Amity University. Since May 2018, she has been contributing to Medical Dialogues, writing and editing medical news articles that translate…
John M. Mandrola, MD John M. Mandrola, MD, has disclosed no relevant financial relationships. I see three lessons for cardiologists and researchers alike. But first let's lay out why experts thought these drugs had promise. It's remarkable how much sense these drugs…
Design, endpoints, enrollment, interim reads, and post‑market surveillance.
An article joins this feed when it matches these terms. Each one is also a search of its own.